With a number needed to harm of 13, acarbose was the agent with the highest side-effect-related study dropout rates when compared to other glucose-lowering agents (metformin, SGLT2-i, GLP1-RAs, SU, DPP4 inhibitors) used in T1D as shown in a meta-analysis [29]. Here, SLC5A2 is linked to type 1 diabetes mellitus.